AICAR

Resumen del Protocolo

Resumen conciso del once-daily research regimen.

• Research Objetivo:Activate AMPK pathways to mimic exercise-like metabolic effects.
• Programa:Inyecciones subcutáneas diarias por 8–12 semanas (research protocols).
• Rango de dosis:1,000–3,000 mcg daily (conservative); up to 5,000 mcg in advanced protocols.
• Reconstitución:3.0 mL per 50 mg vial (~16.7 mg/mL) for precise measurements.
• Almacenamiento:Liofilizado y congelado a −20 °C (−4 °F); reconstituted refrigerated 2–8 °C (35.6–46.4 °F) por hasta 4 semanas.

Protocolo de Dosis

Suggested gradual titration approach for research.

• Inicio:1,000 mcg daily; increase by 1,000 mcg cada 2 semanas según tolerancia.
• Dosis Objetivo:2,000–3,000 mcg daily by Semanas 3–8 (conservative).
• Advanced:Up to 5,000 mcg daily if supported by protocol design.
• Frecuencia:Una vez al día (subcutáneo); maintain consistent AMPK activation.
• Momento de aplicación:Any consistent time; rotar sitio de inyeccións daily.

Pasos para Reconstituir

• Extraer3.0 mLde agua bacteriostática con una jeringa estéril.
• Inyectar lentamente por la pared del vial; evitar que haga espuma.
• Girar suavemente hasta que se disuelva (no agitar).
• Label and refrigerate at2–8 °C (35.6–46.4 °F), protegido de la luz.

Posibles Beneficios

Observations from preclinical and limited human research.

• Endurance Mejorarment:Sedentary mice treated with AICAR showed a remarkable +44% increase in endurance without training, demonstrating exercise-mimetic effects.
• Metabolic Mejorarments:Aumentars mitochondrial enzymes, fatty-acid oxidation capacity, and skeletal muscle glucose uptake ; improves insulin sensitivity in animal models.
• Therapeutic Potential:Research suggests potential for diabetic neuropathy protection and metabolic syndrome treatment in animal models.
• Safety Profile:Human trials (acadesine, IV) showed tolerable safety up to 210 mg/kg single dose with only mild, transient side effects ; research subcutaneous doses are a small fraction of this.
• Side Effects:Generally well tolerated in studies; possible mild inyectarion-site reactions (redness, irritación) with subcutaneous use.
• Important:Despite promising preclinical results, AICAR remains experimental; no confirmed clinical benefit in humans has been established, and long-term risks are unknown.